ADMA Biologics Inc(ADMA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ADMA ADMA Biologics Inc

未开盘 04-10 16:00:00 EDT

9.70

-0.24

-2.41%

盘后9.71

+0.01+0.10%

19:59 EDT

最高10.03	最低9.66	成交量387.91万
今开9.88	昨收9.94	日振幅3.72%
总市值23.09亿	流通市值22.68亿	总股本2.38亿
成交额3,785万	换手率1.66%	流通股本2.34亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ADMA","market":"US","secType":"STK","nameCN":"ADMA Biologics Inc","latestPrice":9.7,"timestamp":1775851200000,"preClose":9.94,"halted":0,"volume":3879052,"hourTrading":{"tag":"盘后","latestPrice":9.71,"preClose":9.7,"latestTime":"19:59 EDT","volume":345010,"amount":3346961.7559,"timestamp":1775865578444,"change":0.01,"changeRate":0.001031,"amplitude":0.005155},"delay":0,"changeRate":-0.024144869215291773,"floatShares":233862209,"shares":237997765,"eps":0.6,"marketStatus":"未开盘","change":-0.24,"latestTime":"04-10 16:00:00 EDT","open":9.88,"high":10.03,"low":9.6601,"amount":37846614.76063199,"amplitude":0.037213,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.6,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1776067200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.94,"preHourTrading":{"tag":"盘前","latestPrice":9.85,"preClose":9.94,"latestTime":"09:29 EDT","volume":2424,"amount":24152.750544,"timestamp":1775827799999,"change":-0.09,"changeRate":-0.009054,"amplitude":0.036217},"postHourTrading":{"tag":"盘后","latestPrice":9.71,"preClose":9.7,"latestTime":"19:59 EDT","volume":345010,"amount":3346961.7559,"timestamp":1775865578444,"change":0.01,"changeRate":0.001031,"amplitude":0.005155},"volumeRatio":0.817067437196678,"impliedVol":1.0278,"impliedVolPercentile":0.9679},"requestUrl":"/m/hq/s/ADMA","defaultTab":"news","newsList":[{"id":"1151526092","title":"ADMA Biologics 驳斥关键指控，以澄清市场对其商业惯例与运营的误解","url":"https://stock-news.laohu8.com/highlight/detail?id=1151526092","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151526092?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:06","pubTimestamp":1774609617,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc (ADMA Biologics) 针对近期市场流传的若干关键指控予以坚决驳斥。此举旨在消除外界对其商业运营模式和日常操作所产生的困惑与误解。公司明确表示，其业务实践严格遵守相关法规，运营活动透明且规范。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175737022","title":"ADMA Biologics：作为标准免疫球蛋白治疗失败患者的后线疗法，Asceniv 定位独特并享有溢价定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1175737022","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175737022?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:04","pubTimestamp":1774609444,"startTime":"0","endTime":"0","summary":"对于标准免疫球蛋白治疗反应不佳的患者群体，ADMA Biologics Inc 旗下的 Asceniv 凭借其独特的治疗定位，已成为重要的后线治疗方案。该产品的差异化优势使其在市场中独树一帜，进而支撑了其较高的定价水平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149236728","title":"ADMA Biologics Inc驳斥做空报告：指其曲解Asceniv在IVIG市场效用与竞争定位","url":"https://stock-news.laohu8.com/highlight/detail?id=1149236728","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149236728?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:03","pubTimestamp":1774609394,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc近日回应一份做空报告，明确指出该报告对旗下产品Asceniv在静脉注射免疫球蛋白（IVIG）市场的实际效用及竞争地位存在严重曲解和混淆。公司强调，报告中的指控未能准确反映Asceniv的临床价值与市场定位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159924090","title":"ADMA Biologics 发布声明驳斥 Culper Research 毫无根据、误导且不实的指控","url":"https://stock-news.laohu8.com/highlight/detail?id=1159924090","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159924090?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:01","pubTimestamp":1774609283,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc (ADMA Biologics) 已就 Culper Research 近期发布的报告发表正式声明。该公司明确指出，该报告中的指控均属毫无根据、具有误导性且内容失实。ADMA Biologics 坚决否认报告中的所有不实陈述，并致力于维护其运营的完整性及对股东和患者的承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140548613","title":"ADMA Biologics：做空报告依据不明来源的推测性论断，可信度存疑","url":"https://stock-news.laohu8.com/highlight/detail?id=1140548613","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140548613?lang=zh_cn&edition=full","pubTime":"2026-03-25 18:32","pubTimestamp":1774434723,"startTime":"0","endTime":"0","summary":"一份针对ADMA Biologics Inc (ADMA Biologics) 的做空报告，其核心论点似乎建立在推测性论断之上，而这些论断的来源既不明朗，也缺乏可靠性支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100408182","title":"异动解读 | ADMA Biologics宣布加速股票回购协议，盘中大涨5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100408182","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100408182?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:43","pubTimestamp":1772462580,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc（ADMA）今日盘中大涨5.20%，引起了市场的广泛关注。消息面上，ADMA Biologics宣布与摩根大通达成一项规模达1.25亿美元的加速股票回购协议，该协议是其2026年总额2亿美元股票回购计划的重要组成部分。此举彰显了管理层对公司长期价值的信心，并体现了其优化资本结构、提升股东回报的坚定承诺。根据协议，ADMA将通过此次加速回购机制立即回购大部分预定股份，约占回购计划总额的62.5%。市场分析认为，股票回购计划通常被视为积极的资本配置行动，可能减少流通股数量，从而对股价产生支撑和提振作用。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125548186","title":"ADMA Biologics宣布与摩根大通达成1.25亿美元快速股票回购协议，作为2026年总额2亿美元股票回购计划组成部分","url":"https://stock-news.laohu8.com/highlight/detail?id=1125548186","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125548186?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:02","pubTimestamp":1772452979,"startTime":"0","endTime":"0","summary":"ADMA Biologics近日宣布与摩根大通达成一项规模达1.25亿美元的加速股票回购协议。这项交易是该公司2026年总额2亿美元股票回购计划的重要环节，标志着其资本配置战略进入新阶段。根据协议条款，ADMA将通过此次加速回购机制立即回购大部分预定股份。通过灵活运用现金储备实施股份回购，ADMA旨在平衡业务增长需求与股东利益最大化。剩余部分将根据市场条件和监管要求适时推进。这种分阶段执行策略既保持了财务灵活性，又为未来潜在投资机会预留了空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614886038","title":"Adma Biologics Inc盘中异动 急速下挫5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614886038","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614886038?lang=zh_cn&edition=full","pubTime":"2026-02-25 04:22","pubTimestamp":1771964533,"startTime":"0","endTime":"0","summary":"北京时间2026年02月25日04时22分，Adma Biologics Inc股票出现异动，股价快速下跌5.10%。截至发稿，该股报15.46美元/股，成交量155.45万股，换手率0.65%，振幅5.40%。Adma Biologics Inc股票所在的生物技术行业中，整体涨幅为0.01%。Adma Biologics Inc公司简介：ADMA Biologics Inc是一家端到端的商业生物制药公司，致力于生产、营销和开发特殊的血浆衍生生物制剂，用于治疗有感染风险的免疫缺陷患者和其他有某些传染病风险的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602250422139541d933&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602250422139541d933&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518244776","title":"Adma Biologics Inc2024财年实现净利润1.98亿美元，同比增加801.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518244776","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518244776?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449682,"startTime":"0","endTime":"0","summary":"3月9日，Adma Biologics Inc公布财报，公告显示公司2024财年净利润为1.98亿美元，同比增加801.13%；其中营业收入为4.26亿美元，同比增加65.12%，每股基本收益为0.85美元。从资产负债表来看，Adma Biologics Inc总负债1.38亿美元，其中短期债务1.22百万美元，资产负债比为3.55，流动比率为0.06。机构评级：截至2025年3月9日，当前有3家机构对Adma Biologics Inc目标价做出预测，其中目标均价为27.33美元，其中最低目标价为25.00美元，最高目标价为32.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000250abef98ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000250abef98ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517910218","title":"Adma Biologics Inc盘中异动 急速拉升5.11%报17.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517910218","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517910218?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:42","pubTimestamp":1741185758,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时42分，Adma Biologics Inc股票出现波动，股价快速上涨5.11%。截至发稿，该股报17.88美元/股，成交量38.2961万股，换手率0.16%，振幅5.35%。Adma Biologics Inc股票所在的生物技术行业中，整体涨幅为0.70%。Adma Biologics Inc公司简介：ADMA Biologics Inc是一家端到端的商业生物制药公司，致力于生产、营销和开发特殊的血浆衍生生物制剂，用于治疗有感染风险的免疫缺陷患者和其他有某些传染病风险的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224238a260cb48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224238a260cb48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516670663","title":"坎托菲茨杰拉德公司：重申ADMA Biologics(ADMA.US)评级，由增持调整至增持评级, 目标价由25.00美元调整至25.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516670663","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516670663?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:54","pubTimestamp":1741100071,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：重申ADMA Biologics(ADMA.US)评级，由增持调整至增持评级, 目标价由25.00美元调整至25.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04225448522189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516672229","title":"Adma Biologics Inc盘中异动 快速下跌8.47%报14.49美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516672229","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516672229?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:32","pubTimestamp":1741098761,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时32分，Adma Biologics Inc股票出现异动，股价急速下挫8.47%。Adma Biologics Inc股票所在的生物技术行业中，整体涨幅为0.25%。Adma Biologics Inc公司简介：ADMA Biologics Inc是一家端到端的商业生物制药公司，致力于生产、营销和开发特殊的血浆衍生生物制剂，用于治疗有感染风险的免疫缺陷患者和其他有某些传染病风险的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223241a25f04e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223241a25f04e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116609081","title":"ADMA Biologics 2024年第四季度调整后每股收益（EPS）为0.14美元，低于预期的0.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1116609081","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116609081?lang=zh_cn&edition=full","pubTime":"2025-03-04 05:18","pubTimestamp":1741036692,"startTime":"0","endTime":"0","summary":"ADMA Biologics 2024年第四季度调整后每股收益（EPS）为0.14美元，低于预期的0.15美元。以上内容来自Benzinga Earnings专栏，原文如下：ADMA Biologics Q4 2024 Adj. EPS $0.14 Misses $0.15 Estimate","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188235161","title":"ADMA Biologics 2024年第四季度 GAAP 每股收益 $0.46，销售额 $117.549M 超过预期 $112.800M","url":"https://stock-news.laohu8.com/highlight/detail?id=1188235161","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188235161?lang=zh_cn&edition=full","pubTime":"2025-03-04 05:08","pubTimestamp":1741036126,"startTime":"0","endTime":"0","summary":"ADMA Biologics 2024年第四季度 GAAP 每股收益 $0.46，销售额 $117.549M 超过预期 $112.800M以上内容来自Benzinga Earnings专栏，原文如下：ADMA Biologics Q4 2024 GAAP EPS $0.46, Sales $117.549M Beat $112.800M Estimate","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ADMA Biologics 2024年第四季度 GAAP 每股收益 $0.46，销售额 $117.549M 超过预期 $112.800M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516535309","title":"Adma Biologics Inc盘中异动 股价大涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516535309","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516535309?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:26","pubTimestamp":1740774377,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时26分，Adma Biologics Inc股票出现异动，股价大幅上涨5.12%。截至发稿，该股报16.23美元/股，成交量157.227万股，换手率0.67%，振幅6.15%。Adma Biologics Inc股票所在的生物技术行业中，整体涨幅为0.41%。Adma Biologics Inc公司简介：ADMA Biologics Inc是一家端到端的商业生物制药公司，致力于生产、营销和开发特殊的血浆衍生生物制剂，用于治疗有感染风险的免疫缺陷患者和其他有某些传染病风险的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301042618a2585202&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301042618a2585202&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181224715","title":"异动解读 | ADMA生物技术公司上涨5.21%,财务数据向好或为主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1181224715","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181224715?lang=zh_cn&edition=full","pubTime":"2025-01-15 23:10","pubTimestamp":1736953823,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc (ADMA) 今日盘中大涨5.21%,引起了市场的广泛关注。\n从公开的财务数据来看,这家生物技术公司最新季度实现营业收入1.2亿美元,净利润3591万美元,每股收益0.15美元,毛利5963万美元,财务数据向好或是推动股价上涨的主因。\n此外,机构评级给予较高评价也值得关注。公开资料显示,100%的分析机构对该股给予买入评级,未有持有或卖出评级,有力支撑了股价上行预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | ADMA生物技术公司上涨5.21%,财务数据向好或为主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503695628","title":"Adma Biologics Inc盘中异动 早盘急速上涨5.39%报17.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503695628","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503695628?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:31","pubTimestamp":1736951467,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时31分，Adma Biologics Inc股票出现波动，股价快速上涨5.39%。截至发稿，该股报17.20美元/股，成交量5.1367万股，换手率0.02%，振幅1.89%。Adma Biologics Inc股票所在的生物技术行业中，整体涨幅为0.68%。Adma Biologics Inc公司简介：ADMA Biologics Inc是一家端到端的商业生物制药公司，致力于生产、营销和开发特殊的血浆衍生生物制剂，用于治疗有感染风险的免疫缺陷患者和其他有某些传染病风险的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223108a222fd7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223108a222fd7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503835315","title":"Adma Biologics Inc盘中异动 早盘快速下挫5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503835315","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503835315?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:34","pubTimestamp":1736778892,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时34分，Adma Biologics Inc股票出现异动，股价快速下跌5.06%。Adma Biologics Inc股票所在的生物技术行业中，整体跌幅为0.99%。Adma Biologics Inc公司简介：ADMA Biologics Inc是一家端到端的商业生物制药公司，致力于生产、营销和开发特殊的血浆衍生生物制剂，用于治疗有感染风险的免疫缺陷患者和其他有某些传染病风险的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223452a220405a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223452a220405a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2501278610","title":"Adma Biologics Inc盘中异动 早盘股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501278610","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501278610?lang=zh_cn&edition=full","pubTime":"2025-01-07 23:32","pubTimestamp":1736263923,"startTime":"0","endTime":"0","summary":"北京时间2025年01月07日23时32分，Adma Biologics Inc股票出现异动，股价急速下挫5.10%。截至发稿，该股报18.16美元/股，成交量45.0653万股，换手率0.19%，振幅5.72%。Adma Biologics Inc股票所在的生物技术行业中，整体涨幅为1.29%。Adma Biologics Inc公司简介：ADMA Biologics Inc是一家端到端的商业生物制药公司，致力于生产、营销和开发特殊的血浆衍生生物制剂，用于治疗有感染风险的免疫缺陷患者和其他有某些传染病风险的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107233203a218f592&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107233203a218f592&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2500972693","title":"Adma Biologics Inc盘中异动 股价大涨5.07%报18.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500972693","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500972693?lang=zh_cn&edition=full","pubTime":"2025-01-03 01:16","pubTimestamp":1735838184,"startTime":"0","endTime":"0","summary":"北京时间2025年01月03日01时16分，Adma Biologics Inc股票出现异动，股价快速上涨5.07%。截至发稿，该股报18.02美元/股，成交量65.3496万股，换手率0.28%，振幅5.19%。Adma Biologics Inc股票所在的生物技术行业中，整体涨幅为0.70%。Adma Biologics Inc公司简介：ADMA Biologics Inc是一家端到端的商业生物制药公司，致力于生产、营销和开发特殊的血浆衍生生物制剂，用于治疗有感染风险的免疫缺陷患者和其他有某些传染病风险的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103011624ab9c1be1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103011624ab9c1be1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ADMA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.admabiologics.com","stockEarnings":[{"period":"1week","weight":0.0555},{"period":"1month","weight":-0.381},{"period":"3month","weight":-0.4596},{"period":"6month","weight":-0.3329},{"period":"1year","weight":-0.4807},{"period":"ytd","weight":-0.4682}],"compareEarnings":[{"period":"1week","weight":0.036},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.021},{"period":"6month","weight":0.0405},{"period":"1year","weight":0.2952},{"period":"ytd","weight":-0.0036}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ADMA Biologics, Inc.于2004年6月24日作为新泽西州公司成立，并于2007年7月16日在特拉华州重新注册。该公司是一家总部位于美国的端到端商业化生物制药公司，致力于为免疫缺陷患者和有特定传染病风险的人群制造、营销和开发专科生物制品。它销售三种经FDA批准的产品——ASCENIV、BIVIGAM和Nabi-HB，这些产品在其位于佛罗里达州的工厂生产，并运营着获得FDA许可的血浆采集中心。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.021016},{"month":2,"riseRate":0.5,"avgChangeRate":-0.01871},{"month":3,"riseRate":0.583333,"avgChangeRate":0.064012},{"month":4,"riseRate":0.666667,"avgChangeRate":0.029121},{"month":5,"riseRate":0.636364,"avgChangeRate":0.053968},{"month":6,"riseRate":0.181818,"avgChangeRate":-0.056361},{"month":7,"riseRate":0.727273,"avgChangeRate":0.105206},{"month":8,"riseRate":0.272727,"avgChangeRate":0.003287},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.032166},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.041559},{"month":11,"riseRate":0.636364,"avgChangeRate":0.093715},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.060542}],"exchange":"NASDAQ","name":"ADMA Biologics Inc","nameEN":"ADMA Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ADMA Biologics Inc(ADMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ADMA Biologics Inc(ADMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ADMA Biologics Inc,ADMA,ADMA Biologics Inc股票,ADMA Biologics Inc股票老虎,ADMA Biologics Inc股票老虎国际,ADMA Biologics Inc行情,ADMA Biologics Inc股票行情,ADMA Biologics Inc股价,ADMA Biologics Inc股市,ADMA Biologics Inc股票价格,ADMA Biologics Inc股票交易,ADMA Biologics Inc股票购买,ADMA Biologics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ADMA Biologics Inc(ADMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ADMA Biologics Inc(ADMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}